Journal article
The Role of Aluminum in the Functional Iron Deficiency of Patients Treated With Erythropoietin: Case Report of Clinical Characteristics and Response to Treatment
Abstract
The quantitative variation among patients in their response to erythropoietin can be explained, in part, by factors that can independently cause anemia in patients with end-stage renal disease. Aluminum can blunt the effect of erythropoietin, in part by interfering with iron bioavailability. This inhibitory effect cannot be completely overcome by aggressive ferrotherapy, but can be reversed with aluminum chelation therapy. A patient is …
Authors
Donnelly SM; Smith EKM
Journal
American Journal of Kidney Diseases, Vol. 16, No. 5, pp. 487–490
Publisher
Elsevier
Publication Date
November 1990
DOI
10.1016/s0272-6386(12)80065-5
ISSN
0272-6386